Children's Hospital Colorado

Hyundai and Hyundai Colorado Dealers Donate $150,000 to Children's Hospital Colorado During the 2024 Alice Cares for Kids Radiothon™

Retrieved on: 
Thursday, March 21, 2024
Health, Humanity, SUV, Hyundai Motor America, Patient, Hyundai Motor Company, Research, Children's Hospital Colorado, Child, Alice Cares, Multimedia, Family, Hospital

DENVER, March 21, 2024 /PRNewswire/ -- Hyundai Motor America and local Hyundai Colorado dealers recently donated $150,000 to Children's Hospital Colorado as part of the 2024 Alice 105.9's (KALC-FM) annual Alice Cares for Kids Radiothon™.

Key Points: 
  • DENVER, March 21, 2024 /PRNewswire/ -- Hyundai Motor America and local Hyundai Colorado dealers recently donated $150,000 to Children's Hospital Colorado as part of the 2024 Alice 105.9's (KALC-FM) annual Alice Cares for Kids Radiothon™.
  • "Hyundai is proud to once again come together with the Colorado Hyundai Dealers to show support for an important cause—the health and wellbeing of our children," said John Angevine, general manager, mountain states region, Hyundai Motor America.
  • "Children's Hospital Colorado is a remarkable institution whose work saves lives by delivering high-quality patient care to people in need."
  • Hyundai Motor America offers U.S. consumers a technology-rich lineup of cars, SUVs, and electrified vehicles, while supporting Hyundai Motor Company's Progress for Humanity vision.

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Retrieved on: 
Thursday, November 9, 2023
Webcast, Editorial, Safety, BLA, Month, DBV Technologies, Asthma, Risk, Database, Patient, OLE, FDA, American College, DBV, EST, Children's Hospital Colorado, Immunotherapy, Food allergy, ACAAI, Anaphylaxis, Pharmaceutical industry, Dietary supplement, Vaccine, Cryptocurrency, Wine, Silviculture, Euronext

Company to host investor conference call and webcast at 5:00pm ET today, Thursday, November 9th, to discuss the results.

Key Points: 
  • Company to host investor conference call and webcast at 5:00pm ET today, Thursday, November 9th, to discuss the results.
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive interim results from its ongoing Open-Label Extension (OLE) Study of EPITOPE (Phase 3 trial of Viaskin™ Peanut 250 µg [VP250] in toddlers ages 1 to 3 years), which is named EPOPEX.
  • After completing participation in the EPITOPE study, eligible subjects could enroll in EPOPEX to receive a total of three years of Viaskin Peanut treatment.
  • “We are thrilled with the results generated from the two-year open-label extension to the Phase 3 EPITOPE trial.

Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

Retrieved on: 
Thursday, November 30, 2023
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Safety, Senior, Ageing, Prader–Willi syndrome, Choking, ACAD, Patient, PWS, TID, Metabolism, FDA, Medical Affairs Bureau, COMPASS, United, Polyphagia, Children's Hospital Colorado, Hunger, Pharmaceutical industry, Genetics

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS).

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
  • “Essentially all experience hyperphagia, feeling a near-constant state of hunger, as though their body is telling them that they are starving, despite being actually well-nourished.
  • The primary efficacy endpoint of the study is change from baseline to week 12 on the hyperphagia questionnaire for clinical trials (HQ-CT) score, a caregiver assessment for hyperphagia-related behaviors.
  • Participants who complete the Phase 3 study will be eligible to enroll in a long-term, open-label extension study designed to investigate the safety and tolerability of long-term treatment with ACP-101.

New SeriousFun Children's Network Study Discovers Improved Sense of Purpose in Medical Volunteers

Retrieved on: 
Thursday, November 9, 2023
Children's Hospital Colorado, Rejuvenation, National Association Medical Staff Services, Caregiver, Volunteering, Frustration, University of Colorado School of Medicine, Medicine, SeriousFun Children's Network, Patient, University, Nursing, Tourism, Network

NORWALK, Conn., Nov. 9, 2023 /PRNewswire/ -- SeriousFun Children's Network (SeriousFun), the leading network of medical specialty camps in the world, has released a new report offering unique insight into the potential of medical specialty camps to positively affect the well-being of medical professionals caring for children.

Key Points: 
  • Volunteers reported positive camp experiences with 99% feeling included and a sense of purpose.
  • Importantly, medical volunteers experienced their pediatric patients in a new light which increased appreciation of their positive impact on patients' lives.
  • "SeriousFun recognizes the importance of offering medical providers opportunities to build stress resilience and coping skills that translate to their day-to-day work," said Dr. Laura Blaisdell, Medical Advisor, SeriousFun Children's Network.
  • SeriousFun Children's Network is continuously working to grow its reach and impact by creating positive, inclusive, and empowering experiences for campers, families, caregivers, volunteers, medical professionals, and communities.

DBV Technologies to Present New Data at ACAAI 2023

Retrieved on: 
Thursday, November 2, 2023
Aurora, Panel discussion, FDA, American College, DBV, Food, Biologics license application, ACAAI, Safety, European Medicines Agency, MBA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, PST, Immune system, Risk, Asthma, DRS, DBV Technologies, Allergy, Children's Hospital Colorado, Patient, BLA, Pharmaceutical industry, Vaccine, Euronext

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.
  • The presentation will be available on DBV’s website, www.dbv-technologies.com , following the conclusion of the meeting for those who are unable to attend.
  • In addition, DBV is a 2023 ACAAI Benefactor Level Corporate Council Member.
  • The Company will also host a booth in the ACAAI Exhibit Hall from Saturday, November 11 – Monday, November 13th.

Donor Alliance Honors City of Aurora with 2023 Community of Excellence Award

Retrieved on: 
Friday, October 6, 2023
Philanthropy, Public Policy, Government, State, Local, Health, Surgery, Other Philanthropy, General Health, Partnership, Hope, University of Colorado Hospital, Eye, Culture, Africa-Italy Excellence Awards, University, Transplant, Children's Hospital Colorado, City, Environment, Summer, DMV, Life, Dentistry, Medical device, Imagination

In alignment with Donor Alliance’s mission to save and heal lives through organ and tissue donation and transplantation, today, the nonprofit organization presented its 2023 Donor Alliance Community of Excellence Award to the City of Aurora and its Mayor, Mike Coffman.

Key Points: 
  • In alignment with Donor Alliance’s mission to save and heal lives through organ and tissue donation and transplantation, today, the nonprofit organization presented its 2023 Donor Alliance Community of Excellence Award to the City of Aurora and its Mayor, Mike Coffman.
  • The Donor Alliance Community of Excellence Award recognizes an exceptional individual or organization in the region committed to inspiring and educating their residents about making the decision to give the gift of life.
  • “I’m proud and honored to recognize Mayor Mike Coffman and the City of Aurora,” said Jennifer Prinz, president, and CEO of Donor Alliance.
  • From Summer of Imagination to Global Fest, we will continue to encourage donor registration at city events to benefit underrepresented communities.

7-Eleven, Inc. Unveils Nine College Football Stars Joining This Season's Cleat Crew™

Retrieved on: 
Tuesday, September 19, 2023
Snack, Nationwide Children's Hospital, Hospital, EST, Children's Hospital Colorado, Children's Miracle Network Hospitals, Sale, Dell Children's Medical Center, Athlete, Shoe, Cooking, Medical Center, Dell, PeaceHealth Sacred Heart Medical Center at RiverBend, Chief sustainability officer, Football, Sports equipment, Toy, Tourism, 7-Eleven

IRVING, Texas, Sept. 19, 2023 /PRNewswire/ -- Today, 7-Eleven, Inc. revealed its roster of nine college football athletes joining its first-ever Cleat Crew program, which brings together stars from top-ranked college football programs across the country to raise funds for Children's Miracle Network Hospitals.

Key Points: 
  • IRVING, Texas, Sept. 19, 2023 /PRNewswire/ -- Today, 7-Eleven, Inc. revealed its roster of nine college football athletes joining its first-ever Cleat Crew program, which brings together stars from top-ranked college football programs across the country to raise funds for Children's Miracle Network Hospitals.
  • Proceeds from each sale will directly benefit longtime partner of the 7-Eleven family of brands, Children's Miracle Network Hospitals .
  • Beginning September 21, a new cleat will be revealed on 7-Eleven's (@7eleven) Instagram page each Thursday.
  • More top players in the Cleat Crew include powerhouse wide receiver Marvin Harrison, Jr. and dynamic quarterback Quinn Ewers.

There With Care Serves Its 10,000th Family

Retrieved on: 
Thursday, August 31, 2023
Children's Hospital Colorado, Social, San Francisco Bay Area, Diagnosis, LSW, Hospital, Transport, Family, Attention, Life, Palliative care, Child, Nursing

BOULDER, Colo., Aug. 31, 2023 (GLOBE NEWSWIRE) -- There With Care announces it has served 10,000 families.

Key Points: 
  • BOULDER, Colo., Aug. 31, 2023 (GLOBE NEWSWIRE) -- There With Care announces it has served 10,000 families.
  • Founded in Boulder, Colorado in 2005, There With Care has grown to support families with children facing a medical crisis in Denver, Nashville, and the Bay Area of Northern California.
  • When a child is diagnosed with a critical illness, the wholeness of the family is threatened.
  • “It’s humbling to think about the 10,000 families who have allowed There With Care to provide community and care during one of the most frightening times in their lives,” adds Paula DuPré Pesmen, Founder and CEO.

Goliath Technologies is Revolutionizing Clinician End User Experience Troubleshooting with Industry Only Epic Integration

Retrieved on: 
Wednesday, August 23, 2023
Hyperspace, University, Desktop virtualization, University of Mississippi Medical Center, Electronic health record, Health information technology, Goliath, Cerner, Children's Hospital, HIT, VDI, Children's Hospital Colorado, Hamilton Health Sciences, Hyperdrive, Hospital, Health, CommonSpirit Health, Nursing

PHILADELPHIA, Aug. 23, 2023 /PRNewswire-PRWeb/ -- Goliath Technologies, a leading provider of end-user experience monitoring and troubleshooting solutions, is proud to announce the second version of its Epic Module, which further enhances our exclusive integration designed to help improve clinician and healthcare worker satisfaction with Epic. Goliath is an Epic App Market Member, and our new module is available on the Epic Connection Hub.

Key Points: 
  • PHILADELPHIA, Aug. 23, 2023 /PRNewswire-PRWeb/ -- Goliath Technologies, a leading provider of end-user experience monitoring and troubleshooting solutions, is proud to announce the second version of its Epic Module, which further enhances our exclusive integration designed to help improve clinician and healthcare worker satisfaction with Epic.
  • Goliath is an Epic App Market Member, and our new module is available on the Epic Connection Hub.
  • "Goliath is purpose-built for healthcare IT and stands as the industry standard," says Thomas Charlton, CEO at Goliath Technologies.
  • "Our technology provides the only way to objectively track end user clinician experience and compare the health systems' performance against industry best practices.

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

Retrieved on: 
Monday, August 21, 2023
Infectious Diseases, FDA, Pharmaceutical, Health, Aurora, Inc., Pregnancy, University, Senior, Life, Hospital, Gestational age, Public, Safety, The New England Journal of Medicine, Infection, PFE, Clinical trial, Children's Hospital Colorado, University of Colorado School of Medicine, Development, Protein, RSV, Risk, Respiratory syncytial virus vaccine, Immunization, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Vaccine, Pfizer

ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

Key Points: 
  • ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
  • “We are incredibly grateful to the clinical trial participants and study investigator teams around the world, as well as our Pfizer colleagues, for their commitment to making this vaccine available.
  • These results were published in The New England Journal of Medicine in April 2023.
  • Simões, M.D., Clinical Professor, Pediatrics-Infectious Diseases, University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora.